Controversy over Aduhelm stretches back to its June 2021 approval by the U.S. Food and Drug Administration
Magnitude of association for finasteride and dutasteride with dementia decreased over time and became nonsignificant
More adverse dental outcomes seen with sublingual buprenorphine/naloxone compared with use of transdermal buprenorphine or oral naltrexone
Risk for death, unplanned hospital admission significantly lower for those taking AChEIs only or taking AChEIs and memantine
Number of active buprenorphine episodes comparable to expected number, with fewer initiations and fewer ending of episodes
Individuals who were independently aware of the FDA decision demonstrated reduced willingness to participate
Meta-analysis shows no significant associations for children, adolescents, or adults, for female patients, or for those with preexisting CVD
Risk for preterm birth, small size for gestational age, low birth weight lower for those receiving buprenorphine versus methadone
Moderately less decline seen in cognition and function at 18 months with lecanemab versus placebo
No significantly increased risk seen for ADHD or ASD with exposure to benzodiazepines during first, second, third trimester